Claims
- 1. A method for eliciting neural fiber growth within the central nervous system to treat a patient with a neurologic disease or injury, comprising:gaining access to the central nervous system of the patient in need of such a treatment; and contacting the central nervous system with microspheres comprising a neuroactive molecule encapsulated within a polymer, wherein the micropsheres comprising an effective amount of neuroactive molecule are capable of eliciting neural fiber growth, said polymer (1) being permeable to the neuroactive molecule agent, (2) being biocompatible with the tissues of the central nervous system, (3) being biodegradable within the tissues of the central nervous system without producing toxic by-products of degradation, and (4) having kinetic characteristics that may be manipulated to allow for the permeation of the neuroactive molecule through the polymer at a controlled rate and a predetermined period of time, thereby eliciting neural fiber growth within the central nervous system of the patient.
- 2. The method of claim 1, wherein the microspheres have a mean diameter of from about 0.1 μm to about 20 μm.
- 3. The method of claim 1, wherein the microspheres have a mean diameter of from about 0.1 μm to about 10 μm.
- 4. The method of claim 1, wherein the central nervous system does not include the striatum.
- 5. The method of claim 1, wherein the contacting step comprises implanting the micropsheres into a specific anatomical region of the central nervous system.
- 6. The method of claim 1, wherein the contacting step comprises implanting the micropsheres into a specific anatomical region of the central nervous system other than the striatum.
- 7. The method of claim 1, wherein the polymer is biodegradable within the tissues of the central nervous system.
- 8. The method of claim 1, wherein the neuroactive molecule comprises a neurotransmitter, a neurotransmitter mimetic, a neuronal receptor agonist, a neuronal receptor antagonist, a neuropeptide, or a neurotrophic factor.
- 9. The method of claim 1, wherein the neuroactive molecule comprises norepinephrine, epinephrine, serotonin, dopamine, substance P, somatostatin, nerve growth factor, angiotensin II, corticoptropin releasing factor, choline, acetylcholine, cholinergic neurontrophic agents, basic fibroblast growth factor, acidic fibroblast growth factor, brain derived growth factor, insulin growth factor, transforming growth factor β, epidermal growth factor, transforming growth factor, glial derived aminobutyric acid mimetic, oxytocin, phenethyl amine, or interleukin-1.
- 10. The method of claim 1, wherein the neuroactive molecule is dopamine or a dopamine mimetic.
- 11. The method of claim 1, wherein the neuroactive molecule is not dopamine or a dopamine mimetic.
- 12. The method of claim 1, wherein the polymer comprises a polyesteramide, a polyorthoester, a poly β-hydroxybutyric acid, a polyanhydride, a polydiene, a polyalkylene, a polymethacrylate, a polyvinyl ether, a polyvinyl alcohol, a polyvinyl chloride, a polyvinyl ester, a polycarbonate, a polyester, a cellulose ether, a cellulose ester, a polysaccharide, or starch.
- 13. A method according to claim 1, wherein the polymer comprises poly(lactide-co-caprolactone) copolymer, polyhydroxybutyrate-polyhydroxyvalerate copolymer, polybutadiene, polymethyl methacrylate, polyhydroxyethyl methacrylate, polyvinyl acetate, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, cellulose acetate, or cellulose acetate butyrate.
- 14. The method of claim 1, wherein the polymer comprises a poly(lactide-co-glycolide) copolymer, a polylactide homopolymer, or a polyglycolide homopolymer.
- 15. The method of claim 1, wherein the micropshere comprises two or more groups of microspheres, wherein each group contains a different neuroactive molecule.
- 16. The method of claim 1, wherein the neuroactive molecule is dopamine and the polymer is a poly(lactide-co-glycolide) copolymer.
- 17. The method of claim 1, wherein the neuroactive molecule is dopamine and the polymer is a polycaprolactone.
- 18. The method of claim 1, wherein the neuroactive molecule is dopamine and the polymer is a polyhydroxybutyrate-polyhydroxyvalerate copolymer.
- 19. The method of claim 1, wherein the neuroactive molecule is noradrenaline and the polymer is a poly(lactide-co-glycolide) copolymer.
- 20. The method of claim 1, wherein the neuroactive molecule is norepinephrine and the polymer is a poly(lactide-co-glycolide) copolymer.
- 21. The method of claim 1, wherein the neuroactive molecule is from 1% to 80% by weight of the microsphere.
- 22. The method of claim 1, wherein the treatment is for a patient with a neurologic disease and the neurologic disease is Parkinson's disease, amyotrophic lateral sclerosis, Huntington's chorea, Alzheimer's disease, epilepsy, or tardive dyskinesia.
- 23. The method of claim 1, wherein the treatment is for a patient with a neurologic injury and the neurologic injury is a spinal cord injury.
- 24. The method of claim 1, wherein the central nervous system is brain tissue.
- 25. The method of claim 1, wherein the central nervous system is spinal cord tissue.
Parent Case Info
This application is a continuation of U.S. application Ser. No. 08/268,177, filed Jun. 29, 1994, now allowed, which is a continuation-in-part of U.S. application Ser. No. 08/033,309, filed Mar. 15, 1993, U.S. Pat. No. 5,360,610, which is a continuation of U.S. application Ser. No. 07/525,383, filed May 16, 1990, abandoned. All of the above applications are hereby incorporated by this reference in their entireties for all of their teachings.
US Referenced Citations (6)
Number |
Name |
Date |
Kind |
4832686 |
Anderson |
May 1989 |
A |
4883666 |
Sabel et al. |
Nov 1989 |
A |
4962091 |
Eppstein et al. |
Oct 1990 |
A |
4994281 |
Muranishi et al. |
Feb 1991 |
A |
5225205 |
Orsolini |
Jul 1993 |
A |
5360610 |
Tice et al. |
Nov 1994 |
A |
Foreign Referenced Citations (9)
Number |
Date |
Country |
4023134 |
Jan 1991 |
DE |
0058481 |
Aug 1982 |
EP |
0145240 |
Jun 1985 |
EP |
0251631 |
Jan 1988 |
EP |
0377477 |
Jul 1990 |
EP |
0412554 |
Feb 1991 |
EP |
60048923 |
Mar 1985 |
JP |
WO 9015637 |
Dec 1990 |
WO |
WO 9117772 |
Nov 1991 |
WO |
Non-Patent Literature Citations (4)
Entry |
Emmett et al. Visualization of migration of transplated astrocytes using polystyrene microspheres. Brain Res. 447:223-233 (1988). |
Howard et al. “Intracerebral drug delivery in rats with lesion-induced memory deficits,” J. Neurosurg., 71:105-112 (1989). |
Maulding “Prolonged delivery of peptides by microcapsules,” J. Controlled Release, 6:167-176 (1987) (abstract). |
McRae-Degueurce et al. “Implantable microencapsuled dopamine (DA): a new approach for slow-release DA delivery into brain tissue,” Neuroscience Letters, 92:303-309 (1992). |
Continuations (2)
|
Number |
Date |
Country |
Parent |
08/268177 |
Jun 1994 |
US |
Child |
09/934382 |
|
US |
Parent |
07/525383 |
May 1990 |
US |
Child |
08/033309 |
|
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
08/033309 |
Mar 1993 |
US |
Child |
08/268177 |
|
US |